 Heidelberg, Germany, April 12, 2021 Affimed N.V. Nasdaq: AFMD, a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announces pre-clinical data on its Innate Cell Engager ICE AFM24 as monotherapy and in combination with adoptively transferred NK cells at the American Association for Cancer Research AACR Virtual Annual Meeting I. 